ReviewBehavioural pharmacology2015
Endocannabinoids and striatal function: implications for addiction-related behaviours.
Review in Behavioural pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Neuromodulators of orbitofrontal cortex function: A review of endocannabinoid, neurotrophin, and cell adhesion systems.Neurobiology of disease · 2026Review
- Cannabinoid type 1 receptor availability imaging in attention-deficit/hyperactivity disorder using [EJNMMI reports · 2026Article
- Dependence of psychopharmacological drug effects on early social stress experience: An analysis aligned with the research domain criteria framework.The Journal of pharmacology and experimental therapeutics · 2025Review
- Genetic variation in endocannabinoid signaling: Anxiety, depression, and threat- and reward-related brain functioning during the transition into adolescence.Behavioural brain research · 2024Article
- Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 density.Translational psychiatry · 2023Article
- Effects of β -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction.Current neuropharmacology · 2023Article
- Endocannabinoid signaling of homeostatic status modulates functional connectivity in reward and salience networks.Psychopharmacology · 2022Article
- Alterations of Stress-Related Glucocorticoids and Endocannabinoids in Hair of Chronic Cocaine Users.The international journal of neuropsychopharmacology · 2022Article
- Therapeutic Potential of Monoacylglycerol Lipase (MGL) Inhibitors as Treatment for Pain, Depression, Cancers, and Eye Conditions.ACS medicinal chemistry letters · 2022Article
- Alcohol-Endocannabinoid Interactions: Implications for Addiction-Related Behavioral Processes.Alcohol research : current reviews · 2022Review
- Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice.Nature communications · 2020Article
- The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice.Psychopharmacology · 2020Article
- Impact of Sleep Disorder as a Risk Factor for Dementia in Men and Women.Biomolecules & therapeutics · 2020Review
- Neural circuitry and mechanisms of waiting impulsivity: relevance to addiction.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- Impulsive Action and Impulsive Choice Are Differentially Associated With Gene Expression Variations of the GABAFrontiers in behavioral neuroscience · 2019Article
- Fatty acid-binding proteins 5 and 7 gene deletion increases sucrose consumption and diminishes forced swim immobility time.Behavioural pharmacology · 2018Article
- Fatty acid binding protein deletion prevents stress-induced preference for cocaine and dampens stress-induced corticosterone levels.Synapse (New York, N.Y.) · 2018Article
- Effects of Estrogens on Central Nervous System Neurotransmission: Implications for Sex Differences in Mental Disorders.Progress in molecular biology and translational science · 2018Review
- The F238L Point Mutation in the Cannabinoid Type 1 Receptor Enhances Basal Endocytosis via Lipid Rafts.Frontiers in molecular neuroscience · 2018Article
- The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders.Child and adolescent psychiatric clinics of North America · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Since the identification and cloning of the major cannabinoid receptor expressed in the brain almost 25 years ago research has highlighted the potential of drugs that target the endocannabinoid system for treating addiction. The endocannabinoids, anandamide and 2-arachidonoyl glycerol, are lipid-derived metabolites found in abundance in the basal ganglia and other brain areas innervated by the mesocorticolimbic dopamine systems. Cannabinoid CB1 receptor antagonists/inverse agonists reduce reinstatement of responding for cocaine, alcohol and opiates in rodents. However, compounds acting on the endocannabinoid system may have broader application in treating drug addiction by ameliorating associated traits and symptoms such as impulsivity and anxiety that perpetuate drug use and interfere with rehabilitation. As a trait, impulsivity is known to predispose to addiction and facilitate the emergence of addiction to stimulant drugs. In contrast, anxiety and elevated stress responses accompany extended drug use and may underlie the persistence of drug intake in dependent individuals. In this article we integrate and discuss recent findings in rodents showing selective pharmacological modulation of impulsivity and anxiety by cannabinoid agents. We highlight the potential of selective inhibitors of endocannabinoid metabolism, directed at fatty acid amide hydrolase and monoacylglycerol lipase, to reduce anxiety and stress responses, and discuss novel mechanisms underlying the modulation of the endocannabinoid system, including the attenuation of impulsivity, anxiety, and drug reward by selective CB2 receptor agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.